10/19/2006 | BT | Serono retains Merrill's neutral rating
|
10/19/2006 | BT | Serono reports strong third quarter, ends period with liquid assets of $2.1 billion
|
10/11/2006 | BT | S&P: Pharmaceutical sales growth spurs mergers
|
9/25/2006 | BT | Merrill cuts Serono to neutral
|
9/21/2006 | BT | Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
|
9/21/2006 | BT | Serono's multiple sclerosis drug cladribine awarded fast-track status
|
9/21/2006 | BTCV | Moody's may downgrade Serono
|
9/21/2006 | BT | Merck to acquire majority shares of Serono for CHF 16.6 billion
|
9/18/2006 | BT | Serono, Syntonix to collaborate on long-acting infertility treatment
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/12/2006 | BT | BioMarin, Serono release Phenoptin data in three clinical studies
|
9/7/2006 | BT | Dyax, Serono enter agreement for antibody discovery
|
8/17/2006 | BT | Serono's r-hGH for treatment of HARS shows positive results in phase 3 trial
|
8/4/2006 | BT | Serono given buy rating by Merrill
|
7/27/2006 | BT | Merrill retains Serono at buy
|
7/26/2006 | BT | Serono reports 3.3% rise in second-quarter revenues to $699.2 million
|
7/10/2006 | BT | Serono's Rebif gets approval for earlier use in multiple sclerosis
|
6/26/2006 | BT | ZymoGenetics, Serono say results of TACI-Ig phase 1b trial in rheumatoid arthritis are promising
|
6/22/2006 | BT | Serono says Raptiva provides 'significant' improvement in plaque psoriasis
|
5/4/2006 | BT | Serono begins recruitment in phase 3 multiple sclerosis trial
|
4/21/2006 | BT | Serono retained at buy by Merrill
|
4/20/2006 | BT | Merrill keeps Serono at buy
|
4/10/2006 | BT | Serono ends talks on selling company, calling bids too low
|
4/10/2006 | BT | Merrill keeps Serono at buy
|
4/10/2006 | BT | Market Commentary: Cougar Biotech goes public via reverse merger, PIPE; Hythiam hammered; Serono sinks by 10%
|
4/4/2006 | BT | Serono submits new formulation of Rebif for multiple sclerosis
|
3/31/2006 | BT | Serono's board seeks to issue more shares in effort to increase capital
|
3/15/2006 | BT | BioMarin, Serono say all primary, secondary endpoints met in Phenoptin study
|
3/9/2006 | BT | Serono stays at buy by Merrill
|
2/9/2006 | BT | Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
|
2/6/2006 | BT | Merrill rates Serono at buy
|
2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
1/24/2006 | BT | Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
|
1/24/2006 | BT | Serono's Gonal-f approved in Japan for treatment of male hypogonadotropic hypogonadism
|
1/9/2006 | BT | Serono's phase 3 trial of r-hGH to treat HIV-associated HARS meets primary, secondary endpoints
|
11/9/2005 | BT | Jefferies maintains Serono at hold
|
11/9/2005 | BT | Merrill retains Serono at buy
|
11/9/2005 | BT | Market Commentary: CombinatoRx surges on debut; Angiotech off; Fisher issues soar; Digene slips on stock sale plans
|
11/9/2005 | BT | Serono study shows MS patients taking Rebif can get flu vaccine
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
11/8/2005 | BT | Serono retains Goldman Sachs to explore strategic alternatives
|
10/28/2005 | BT | Jefferies lowers Serono's target to CHF 915
|
10/25/2005 | BT | Merrill Lynch retains Serono at buy rating
|
10/25/2005 | BT | Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
|
10/17/2005 | BT | Serono retains Merrill buy rating
|
10/17/2005 | BT | Serono settles Serostim investigation
|
10/4/2005 | BT | Serono held by Merrill Lynch at buy
|
10/4/2005 | BT | Market Commentary: CancerVax crashes; Serono slips; Protein Design Labs cheered; Celgene off; Keryx up
|
9/27/2005 | BT | Serono maintained by Jefferies at hold
|
9/13/2005 | BT | Serono maintained by Merrill Lynch at buy
|
8/18/2005 | BT | Serono stays at buy, Merrill says
|
7/20/2005 | BT | Serono reiterated by Merrill Lynch at buy
|
7/13/2005 | BT | Serono may progress while Tysabri slows, Merrill bio/pharma earnings preview says
|
7/13/2005 | BT | S&P rates Serono A-
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
11/10/2003 | CV | New Issue: Serono prices CHF600 million convertibles to yield 1.625%, up 53.8%
|